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Historically, the median overall survival for patients with stage IV melanoma was less than 1 year and the
5-year survival rate was 10%. Recent advances in therapy have raised 5-year survival expectations to
20%. Notably, a subset of melanoma patients who receive immunotherapy with high-dose interleu-
kin-2, and now ipilimumab, can achieve long-term survival of at least 5 years. A major goal in melanoma
research is to increase the number of patients who experience this overall survival beneﬁt. In this review,
we discuss the attributes of immunotherapy and newer targeted agents, and consider how combination
strategies might improve the chances of achieving durable beneﬁt and long-term survival. We also dis-
cuss three areas that we believe will be critical to making further advances in melanoma treatment. To
better understand the clinical proﬁle of patients who achieve long-term survival with immunotherapy,
we ﬁrst present data from ipilimumab clinical trials in which a subset of patients experienced durable
responses. Second, we discuss the limitations of traditional metrics used to evaluate the beneﬁts of
immunotherapies. Third, we consider emerging issues that clinicians are currently facing when making
treatment decisions regarding immunotherapy. A better understanding of these novel treatments may
improve survival outcomes in melanoma, increase the number of patients who experience this overall
survival beneﬁt, and inform the future use of these agents in the treatment of other cancer types.
 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-SA
license (http://creativecommons.org/licenses/by-nc-sa/3.0/).Introduction
Survival outcomes for patients with stage IV melanoma have
traditionally been poor. With standard therapies such asdacarbazine (DTIC), median overall survival (OS) is 6–10 months
and the 5-year survival rate is 10% [1,2]. The recent availability
of ipilimumab and BRAF pathway targeted agents has raised sur-
vival expectations and shifted the treatment paradigm for mela-
noma. An important challenge for the melanoma community is
how to incorporate these new treatments into day-to-day clinical
decision making to maximize the chances that a patient will
experience long-term beneﬁt. In this review, we discuss the clin-
ical attributes of immunotherapy and BRAF pathway targeted
agents when used as monotherapy and their potential to be used
in combination regimens. We also discuss the following issues
that will be critical to making further advances in melanoma
treatment: (1) characteristics of patients who achieve long-term
survival with immunotherapy, (2) the need for improved clinical
trial endpoints that fully capture the clinical beneﬁts of immuno-
therapy, and (3) emerging questions in need of answers to
D. McDermott et al. / Cancer Treatment Reviews 40 (2014) 1056–1064 1057ensure that appropriate treatment decisions are made about
immunotherapy.New treatments: immunotherapy and targeted therapy
Immunotherapy
Initial attempts to improve outcomes in patients with advanced
melanoma focused on the use of high-dose interleukin-2 (HD IL-2),
a cytokine that induces T-cell activation and proliferation [3]. The
rationale for using HD IL-2 to treat advanced melanoma was based
in part on two observations that suggest involvement of the
immune system in the natural history of melanoma. First, a small
proportion of patients experience spontaneous tumor regression
in primary, but not metastatic, tumors in the absence of systemic
intervention, suggesting that melanoma may be an immunologi-
cally modulated malignancy [4]. Second, HD IL-2 demonstrated
promising antitumor activity in murine models [5].
HD IL-2 was evaluated in a series of phase II melanoma trials. In
a US National Cancer Institute study, while only 7% of melanoma
patients treated with HD IL-2 achieved complete regression,
responses weremaintained for up to 91+months [6]. In eight phase
II melanoma trials of HD IL-2, the objective response rate was 16%
with response durations ranging from 1.5 tomore than 122 months
[7,8]. In a randomized, phase III study, the objective response rate
was 6% among 93 patients treated with HD IL-2 [9]. Although HD
IL-2 may provide durable responses of over 10 years in some
patients, its use is limited by severe toxicity that can affect multiple
organ systems (e.g., cardiovascular, respiratory, nervous, renal,
digestive, and skin) [10]. For this reason, HD IL-2 is generally
reserved for selected patients who are treated as inpatients at spe-
cialty centers. The toxicities associatedwith HD IL-2 have prompted
investigations of low-dose IL-2 (LD IL-2) regimens. Although LD IL-2
is less toxic than HD IL-2 [10], it has failed to produce complete and
durable response in melanoma clinical trials [11,12]. Despite these
limitations, the experience with HD IL-2 provides proof-of-concept
that modulation of the immune systemmight offer durable clinical
beneﬁt inmelanoma. In the era ofmore tolerable immunotherapies,
the role of single-agent HD IL-2 remains to be determined, but T-
cell agonist strategies with more limited toxicities will likely play
a role in future combination regimens.
Improvements in our understanding of tumor immunology
have led to the development of targeted immunotherapies aimed
at speciﬁc immune-checkpoints. Immune-checkpoints that are
currently being targeted in melanoma include cytotoxic T-lympho-
cyte-associated antigen 4 (CTLA-4), programmed death-1 (PD-1),
and programmed death ligand-1 (PD-L1). CTLA-4 and PD-1 are
inhibitory receptors with nonoverlapping roles in modulating the
adaptive immune response. CTLA-4 acts primarily early in the
immune response to regulate T-cell proliferation and migration
to the tumor, whereas PD-1 and its ligand PD-L1 regulate T-cell
activation and proliferation at the tumor site [13].
Ipilimumab, which targets CTLA-4, was approved by the US
Food and Drug Administration (FDA) and the European Medicines
Agency in 2011 for the treatment of unresectable or metastatic
melanoma. A survival beneﬁt with ipilimumab was demonstrated
in two randomized, controlled phase III trials (MDX010-20 and
CA184-024) [14,15]. In study MDX010-20, previously treated mel-
anoma patients received ipilimumab 3 mg/kg plus the melanoma
peptide vaccine gp100, ipilimumab 3 mg/kg alone, or gp100 alone
[14]. The median OS for these treatment groups was 10.0, 10.1, and
6.4 months, respectively. The hazard ratio (HR) for death compared
with gp100 alone was 0.68 (p < 0.001) for the ipilimumab plus
gp100 group and 0.66 (p = 0.003) for the ipilimumab-alone group.
In study CA184-024, previously untreated patients receivedipilimumab 10 mg/kg plus DTIC or DTIC plus placebo [15]. The
median OS for these treatment groups was 11.2 and 9.1 months,
respectively (HR, 0.72; p < 0.001).
Data from these and other clinical trials suggest that a propor-
tion of patients treated with ipilimumab can achieve survival of at
least 5 years. In study CA184-025, a companion study of extended
ipilimumab treatment in patients who received ipilimumab in pre-
vious phase II trials, 5-year survival was 16.5% to 17.0% for ipi-
limumab 3 mg/kg and 17.6% to >49% for ipilimumab 10 mg/kg
[16]. In study CA184-024, 5-year survival was 18.2% for ipi-
limumab plus DTIC versus 8.8% for DTIC plus placebo [17]. A
meta-analysis of pooled OS data from ipilimumab trials, which
included data from 1861 melanoma patients, reported a 3-year
OS rate of 22% (95% CI, 20–24%); furthermore, a plateau in the
pooled Kaplan–Meier curve began at approximately 3 years after
initiation of therapy, and extended through follow-up of as long
as 10 years [18]. Importantly, some patients included in the pooled
analysis were no longer receiving treatment, suggesting that treat-
ment-free survival is possible with ipilimumab.
The success of ipilimumab was closely followed by the develop-
ment of additional immune-checkpoint inhibitors, including nivo-
lumab and pembrolizumab (MK-3475), which target PD-1. These
agents have demonstrated clinical activity in early clinical trials
and are being explored in ongoing phase III studies (Table 1). In a
phase 1 study of nivolumab, 28% (26 of 94) of patients with mela-
noma showed an objective response that lasted from 1.9 to
24.9 months [19]. A phase Ib study of pembrolizumab reported
an objective response rate of 38% among 117 evaluable patients
[20]. Whether responses to nivolumab and pembrolizumab will
be similarly durable to responses to ipilimumab remains to be
determined, but preliminary evidence suggests that this may be
the case [21,22].
Preliminary data from phase I clinical trials suggest that anti-
body-mediated targeting of PD-L1 may also be an effective mela-
noma treatment strategy (Table 1). Among 52 evaluable patients
treated with BMS-936559 (MDX 1105), 9 (17%) achieved an objec-
tive response and 14 (27%) had stable disease (SD) lasting 24 weeks
or more [23] (NCT00729664). Antibody-mediated blockade of PD-
L1 with MPDL3280A, another PD-L1 inhibitor, was associated with
objective responses in 9 of 35 evaluable patients, with all
responses ongoing or improving at the time of tumor assessment
[24] (NCT01375842). A phase I clinical trial is also underway to
evaluate the PD-L1 inhibitor MEDI4736 in several advanced tumor
types including melanoma (NCT01693562).
Targeted therapy
Concurrently with the development of the newer immunother-
apies, a better understanding of the biology of melanoma has led to
the development of molecular targeted therapies. The mitogen-
activated protein kinase (MAPK) pathway is one of the major sig-
naling networks involved in melanoma tumorigenesis [25]. A
major driver of this pathway is BRAF, which can initiate a cascade
of events including phosphorylation and activation of MEK. BRAF
mutations are found in 50% of melanomas, with most (70–95%)
consisting of a V600E substitution, while a smaller proportion
(5–30%) are V600K substitutions [26]. Along with ipilimumab,
agents that target BRAF and MEK have now emerged as key treat-
ments for advanced melanoma.
Vemurafenib, an inhibitor of mutant BRAF, was approved by the
FDA in 2011 for the treatment of melanoma patients harboring
the BRAF V600E mutation based on improved OS versus DTIC in
the BRIM-3 phase III study [27]. At a median follow-up of
10.5 months for vemurafenib and 8.4 months for DTIC, median
OS was 13.2 and 9.6 months, respectively (HR, 0.62) [28]. One-year
OS rates were 55% and 43% in patients treated with vemurafenib
Table 1
Selected on-going immunotherapy trials in advanced melanoma.a
Agents (target) NCT No. Phase Study armsb Expected enrollment Primary outcomes Year initial results expected
Single-agent immunotherapy
Nivolumab (PD-1) NCT01721746 (CheckMate 037) 3 Arm 1: Nivo
Arm 2: DTIC or CBDCA + PTX
390 ORR, OS 2015
NCT01721772 (CheckMate 066) 3 Arm 1: Nivo + PCB for DTIC
Arm 2: DTIC + PCB for nivo
410 OS 2015
NCT01844505 (CheckMate 067) 3 Arm 1: Nivo + PCB for ipi + PCB for nivo
Arm 2: Nivo + ipi + PCB for nivo
Arm 3: Ipi + PCB for nivo
915 OS 2016
Pembrolizumab (PD-1) NCT01295827 (P07990/MK-3475-001) 1 Dose-escalation phase:
Arm 1: Pembro (1)
Arm 2: Pembro (3)
Arm 3: Pembro (10)
Comparison of two dosing regimens:
Arm 1: Pembro (q2wk vs. q3wk)
Comparison of two doses:
Arm 1: Pembro (low dose)
Arm 2: Pembro (high dose)
1067 Safety, tumor response,
DCR, biomarker
2015
NCT01704287 (P08719/MK-3475-002) 2 Arm 1: Pembro (low dose)
Arm 2: Pembro (high dose)
Arm 3: CBDCA + PTX, PTX, DTIC, or tem
510 PFS, OS 2015
NCT01866319 (MK-3475-006 AM1) 3 Arm 1: Pembro (regimen 1)
Arm 2: Pembro (regimen 2)
Arm 3: Ipi
645 PFS, OS 2014
MDX1105 (PD-L1) NCT00729664 (CA210-001) 1 Arm 1: MDX1105 (0.1)
Arm 2: MDX1105 (0.3)
Arm 3: MDX1105 (1.0)
Arm 4: MDX1105 (3.0)
Arm 5: MDX1105 (10.0)
286 MTD, DLT 2013
MPDL3280A (PD-L1) NCT01375842 (PCD4989g) 1 Arm 1: MPDL3280A 344 DLT 2014
MEDI4736 (PD-L1) NCT01693562 (CD-ON-MEDI4736-1108) 1 Arm 1: MEDI4736 q2wk
Arm 2: MEDI4736 q3wk
Arm 3: MEDI4736 dose expansion
220 DLT, safety 2015
Immunotherapy combinations
Agents NCT No. Phase Study armsb Expected enrollment Primary outcomes Year initial results expected
Dual immunotherapy
Ipilimumab and nivolumab NCT01024231 (CA209-004) 1 Arm 1: Nivo (0.3) + ipi (3.0)
Arm 2: Nivo (1.0) + ipi (3.0)
Arm 3: Nivo (3.0) + ipi (3.0)
Arm 4: Nivo (10.0) + ipi (3.0)
Arm 5: Nivo (10.0) + ipi (10.0)
Arm 6: Nivo (1.0)
Arm 7: Nivo (3.0)
Arm 8: Nivo (1.0) + ipi (3.0), then nivo (3)
136 Safety 2014
NCT01783938 (CheckMate 064) 2 Arm 1: Nivo (3), then ipi (3)
Arm 2: Ipi (3), then nivo (3)
100 Safety 2014
NCT01844505 (CheckMate 067) 3 Arm 1: Nivo + PCB for ipi + PCB for nivo
Arm 2: Nivo + ipi + PCB for nivo
Arm 3: Ipi + PCB for nivo
915 OS 2016
Ipilimumab and other immunotherapy NCT01134614 (E1608) 2 Arm 1: Ipi + GM-CSF
Arm 2: Ipi
220 OS 2013
NCT01708941 (ECOG-E3611) 2 Arm 1: Ipi (10) + HDI
Arm 2: Ipi (10)
Arm 3: Ipi (3) + HDI
Arm 4: Ipi (3)
88 PFS 2014
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D. McDermott et al. / Cancer Treatment Reviews 40 (2014) 1056–1064 1059and DTIC, respectively. In the BRIM-2 phase II study of previously
treated melanoma patients, median OS was 15.9 months with
vemurafenib treatment [29]. Data suggest that a subset of mela-
noma patients with BRAF V600 mutation may achieve survival
up to 3 years with continuous, twice-daily vemurafenib treatment.
In the BRIM-1 phase I study, 26% of patients treated with vemu-
rafenib were alive at 3 years [30]. Vemurafenib treatment is asso-
ciated with high response rates, but similar to experience with
other therapies based on oncogene-targeted small molecules,
responses require persistent drug administration and are usually
of limited duration (median of 6.7 months [29]) due to the emer-
gence of tumor resistance [31,32].
The melanoma armamentarium expanded again with the FDA
approval of dabrafenib and trametinib. Dabrafenib was approved
for patients with unresectable or metastatic melanoma harboring
the BRAF V600E mutation based on results from a phase III trial
showing improved median progression-free survival (mPFS) versus
DTIC (5.1 months for dabrafenib vs. 2.7 months for DTIC; HR, 0.30;
p < 0.0001) [33]. The MEK inhibitor trametinib was approved for
melanoma patients harboring a BRAF V600E or V600K mutation
based on results from a phase III trial showing improved mPFS ver-
sus DTIC or paclitaxel (4.8 months for trametinib vs. 1.5 months for
DTIC or paclitaxel; HR, 0.45; p < 0.001) [34]. In 2014, the FDA
approved the use of dabrafenib in combination with trametinib
for patients with BRAF V600E- or V600K-mutated melanoma, mak-
ing dabrafenib/trametinib the ﬁrst FDA-approved targeted combi-
nation therapy for this disease [35]. FDA-approval of dabrafenib/
trametinib combination therapy was based on an improved overall
response rate (ORR) and median duration of response versus dab-
rafenib monotherapy in a phase I/II trial (ORR: 76% for dabrafenib/
trametinib combination vs. 54% for dabrafenib monotherapy; med-
ian duration of response: 10.5 months for dabrafenib/trametinib
combination vs. 5.6 months for dabrafenib monotherapy). The
FDA approval of dabrafenib/trametinib combination therapy is
contingent on results of an ongoing phase III trial (Combi-D,
NCT01584648). Survival follow-up data from the above-mentioned
studies continue to mature, with the extent of the potential sur-
vival beneﬁt for combined dabrafenib and trametinib treatment
not yet determined.
Immunotherapy and targeted therapy have clinical proﬁles
with distinct attributes (Table 2). Although both treatment strate-
gies offer the potential for durable response and long-term sur-
vival, current data suggest that patients must remain on
treatment to achieve these outcomes with targeted therapy,
whereas treatment-free survival and durable response are at least
possible with immunotherapy. The following limitations have been
observed for some, but not all, immunotherapies: low response
rates, delayed onset of effect, and immune-related toxicity that
must be managed carefully. In addition, it is difﬁcult to predict
which patients will respond to immunotherapy. By contrast, tar-
geted therapies are associated with high response rates, rapid
onset of effect, and side effects that are generally reversible after
dose adjustment. However, these treatments require continuous,
twice-daily dosing; may elicit resistance within 6–8 months; and
generally do not provide long-lasting beneﬁt after the therapy is
discontinued. Strategies that capitalize on the strengths and over-
come the weaknesses associated with these treatments are needed
and might possibly be achieved through combination and/or
sequencing regimens.Immunotherapy combination strategies
Immunotherapies in combination and sequenced regimens are
being evaluated for their potential to achieve greater survival ben-
eﬁt in advanced melanoma (Table 1). One area of active research is
1060 D. McDermott et al. / Cancer Treatment Reviews 40 (2014) 1056–1064combined blockade of CTLA-4 and PD-1 pathways. The rationale
for this approach is supported by the concept that immune cells
often express multiple immune-checkpoints with non-overlapping
mechanisms of action (Fig. 1) [37].
Ipilimumab in combination with nivolumab is being studied in
melanoma clinical trials (Table 1). A phase melanoma I study
(NCT01024231) identiﬁed 3 mg/kg ipilimumab and 1 mg/kg nivo-
lumab as the maximum tolerated doses for the concurrent regimen
[38]. Among evaluable patients treated at these doses (n = 17), the
objective response rate was 53%, and the disease control rate was
65%, with two patients showing rapid response (P80% tumor
reduction at their ﬁrst scheduled assessment). Among patients
treated with the concurrent regimen (n = 52), 21 had conﬁrmed
objective response ranging from 6+ to 72+ weeks, with ongoing
response observed in 91% of these patients. The most common
grade 3/4 treatment-related adverse events (AEs) were increased
aspartate aminotransferase (13%), increased alanine aminotrans-
ferase (11%), and elevated lipase (13%). Although the incidence of
immune-related toxicity was greater for this combination than
for either single agent, grade 3/4 toxicities were usually reversible
through application of standard immunosuppression-based algo-
rithms. This combination is being further explored in phase II
(NCT01783938) and phase III (NCT01844505) trials in melanoma
(Table 1) and in other tumor types (e.g., renal cell carcinoma
[NCT01472081]; breast cancer, gastric cancer, pancreatic adeno-
carcinoma, and small cell lung cancer [NCT01928394]; recurrent
glioblastoma [NCT02017717]; non-small cell lung cancer
[NCT01454102]; and colon cancer [NCT02060188]).
Ipilimumab in combination with other immunotherapies is also
being studied (Table 1). An ongoing phase II trial is evaluating ipi-
limumab plus granulocyte macrophage colony-stimulating factor
(GM-CSF) versus ipilimumab alone (NCT01134614). Interim data
from this trial suggest that the addition of GM-CSF to ipilimumab
decreases the incidence of high-grade AEs, particularly those
related to pulmonary and gastrointestinal function [39]. Ipi-
limumab with or without high-dose interferon (HDI) is also being
evaluated in a phase II study (NCT01708941).
Ipilimumab is also being combined with BRAF/MEK inhibitors
in clinical trials [40] (Table 1). The rationale for this approach is
based in part on data from preclinical studies, which suggest that
inhibition of the MAPK pathway has a beneﬁcial effect on the
tumor immune microenvironment [41]. A phase I trial
(NCT01400451) of concurrent ipilimumab and vemurafenib was
prematurely closed due to dose-limiting hepatotoxicity, suggesting
that safety issues may limit the use of this combination regimen
[42]. An ongoing phase II study will evaluate the sequential use
of ipilimumab and vemurafenib (NCT01673854) [43]. Ipilimumab
plus dabrafenib with or without trametinib will also be evaluated
in a phase I study (NCT01767454).
Ipilimumab combined with standard cytotoxics is also being
investigated in melanoma clinical trials (Table 1). In study
CA184-024, ipilimumab plus DTIC was associated with higher rates
of hepatotoxicity and lower rates of enterocolitis than those previ-
ously reported with either agent alone, suggesting that the toxicity
proﬁle with this combination strategy is not simply additive of
these two agents [15]. These data highlight the fact that predicting
toxicity with combinations of ipilimumab may not be straightfor-
ward. In a single-arm, phase II study of ipilimumab plus fotemus-
tine (NCT01654692), the immune-related disease control rate was
46.5% in melanoma patients (N = 86) and 50% in patients with
asymptomatic brain metastases (N = 20) [44]. This combination
strategy is being further explored in an ongoing phase III study
(EUDRACT 2012-004301-27). A phase I/II trial will evaluate
ipilimumab combined with temozolomide, cisplatin, interferon
a-2b, or IL-2 (NCT01409174), and a phase II trial will evaluate
ipilimumab combined with carboplatin/paclitaxel (NCT01676649).Ipilimumab in combination with radiotherapy is also being
explored as a potential treatment for advanced melanoma
(Table 1). The clinical beneﬁts associated with radiotherapy are
generally attributed to improved local tumor control; however,
recent reports suggest that radiotherapy administered locally
may improve antitumor immunity globally [45], extending the
application of radiotherapy beyond its traditional role in local
tumor control [46]. For example, ipilimumab in combination with
radiotherapy has been shown to induce an abscopal effect [45], a
phenomenon in which tumor regression occurs at a site distant
from the primary site of radiotherapy. The therapeutic potential
of this treatment combination is being further explored in ongoing
clinical trials. A phase 1 study is investigating the maximum toler-
ated dose of ipilimumab plus radiotherapy in melanoma patients
with brain metastases (NCT01703507). A phase 2 study is evaluat-
ing response rates associated with ipilimumab alone versus ipi-
limumab plus radiotherapy (NCT01689974).
Data derived from these studies will help determine which
treatment regimens are most likely to improve survival outcomes
in patients with advanced melanoma. However, additional work
on the appropriate selection of patients is also needed to maximize
the potential for immunotherapy to improve survival outcomes.
For this reason, another important area of research is characteriz-
ing patients who might achieve extended survival (e.g., OS at a par-
ticular landmark such as 3 or 5 years) with ipilimumab, with the
ultimate goal of identifying biomarkers that may predict patient
response and survival.Characterizing long-term survivors
Long-term survivors among ipilimumab-treated patients have
included those who achieve complete response (CR), partial
response (PR), SD, and, in some cases, progressive disease (PD)
according to modiﬁed World Health Organization (WHO) criteria
[47]. Some patients with PD may actually develop a response or
SD over time, possibly reﬂecting the long time required to build
antitumor immunity in some patients. Unlike with cytotoxic
agents, SD appears to be an important endpoint for ipilimumab
since these patients may still achieve long-term disease control
and/or survival. An important issue related to SD is whether this
response category represents true residual disease or ﬁbrotic tissue
with no residual tumor. In some cases, tumoral masses may appear
to show incomplete regression, when in fact the remaining abnor-
mal tissue is attributable to residual ﬁbrosis. In these cases, an
incorrect assessment of the tumor response could lead to an under-
estimation of the treatment effect [48]. Although imaging tech-
niques can help to distinguish masses with viable tumor from
those with ﬁbrosis [48], false positives are still possible because
the tumor masses being evaluated often contain a dynamic mix-
ture of metastatic tumor and immunotherapy-induced inﬂamma-
tion [49]. Relying on response rates alone as a surrogate may
underestimate eventual survival outcomes.
Durable responses to ipilimumab do not appear to be associated
with known prognostic factors or BRAF-mutation status. Subgroup
analyses from phase III ipilimumab trials suggest that the effect of
ipilimumab on OS is independent of factors such as age, sex,
baseline lactate dehydrogenase levels, and M stage of disease, as
well as prior IL-2 therapy and ECOG performance status [14,15].
A prospective phase II trial has also demonstrated the activity of
ipilimumab at an investigational dose of 10 mg/kg in patients with
brain metastases, particularly when these metastases are stable
and asymptomatic [50]. Data from an Italian expanded access
program suggest that ipilimumab is an effective treatment for
advanced melanoma regardless of BRAF-mutation status. In
this study, the immune-related disease control rate among
Table 2
Attributes of immunotherapy and targeted therapy.
Immunotherapy Targeted therapy
Strengths:
 Potential for durable response
 Potential for long-term survival, potentially off treatment
Strengths:
 Potential for durable response, on treatment
 Potential for long-term survival, on treatment
 High response rates
 Rapid onset of effect
Weaknesses:
 Low response ratesa,b
 Delayed onset of effecta
 Immune-related toxicity that must be carefully manageda
 Difﬁculty predicting patient responders
Weaknesses:
 Continuous, twice-daily dosing
 May elicit resistance within 6–8 months
 Rare evidence of durable response (off treatment)
Examples:
 HD IL-2
 Ipilimumab targeting CTLA-4
 Investigational agents targeting PD-1 pathway
- Nivolumab
- Pembrolizumab
- MDX1105
- MPDL3280A
Examples:
- Vemurafenib (BRAF inhibitor)
- Dabrafenib (BRAF inhibitor)
- Trametinib (MEK inhibitor)
- Dabrafenib/trametinib combination
Evidence of durable beneﬁt?
 HD IL-2
–Durable remission up to 10 yrs in 10% of ptsc
 Ipilimumab
–Long-term survival up to 10 yrs in 20% of ptsd
Evidence of durable beneﬁt?
 Survival data are not mature
a These attributes have been observed with some, but not all, immunotherapies.
b Response rates according to RECIST criteria.
c Atkins et al. 2000 [8].
d Schadendorf et al. 2013 [18].
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(n = 291) patients was 38% and 39%, respectively, with a median
duration of irDC of 13.1 months [51].
Extensive research has been performed to identify potential bio-
markers that can predict response to ipilimumab. These studies
have focused on absolute lymphocyte count (ALC), serum S100B
levels, tumor-inﬁltrating lymphocytes, and molecular tumor signa-
tures [52–56]. In a retrospective analysis of 51 ipilimumab-treated
patients with advanced melanoma, patients with high ALC levels
(P1000/ll) after two ipilimumab treatments had improved med-
ian OS compared to patients with low ALC levels (<1000/ll) (med-
ian OS: 11.9 months with high ALC vs. 1.4 months with low ALC)
[54]. In another study, ipilimumab-treated patients with an NY-
ESO-1-speciﬁc CD8+ T-cell response experienced a signiﬁcant sur-
vival advantage compared to patients without such a response
[53]. Data from a small cohort (N = 27) of melanoma patients trea-
ted with ipilimumab in an expanded access program suggest that
increased circulating levels of inducible T-cell costimulator-posi-
tive T-cells are associated with improved survival at week 7 of
treatment [56]. The ratio between absolute neutrophil and lympho-
cyte counts was also identiﬁed as a potential predictive marker of
survival in this study. Although some of these data are compelling,
additional work is needed to help clarify the predictive value of
putative biomarkers in melanoma. Interested readers are referred
to other reviews for a more in-depth treatment of this topic [57–
60]. In addition to improved patient selection, reﬁned methods of
assessment are also needed to fully capture the clinical beneﬁt of
immunotherapies.Reﬁning assessment of clinical beneﬁt
Assessment of antitumor response in immunotherapy trials has
been challenging because both conventional and nonconventional
response patterns have been observed. Conventional response pat-
terns include CR with an immediate reduction in tumor burden
and SD followed by reduction in tumor burden. Nonconventional
response patterns, which are unique to immunotherapy treatment,
include response following an initial increase in tumor burden(‘‘pseudoprogression’’) and response in the presence of new
lesions. Conventional response patterns rely on tumor shrinkage
to demonstrate antitumor response and are captured by WHO cri-
teria and Response Evaluation Criteria in Solid Tumors. Nontradi-
tional response patterns, which may not directly relate to tumor
shrinkage, may be missed when using these traditional metrics.
The need to fully capture the clinical beneﬁt of these drugs has
led to the development of immune-related response criteria [61].
The kinetics of antitumor immune response also have important
implications for evaluation of survival endpoints in immunotherapy
trials. Kaplan–Meier curves from immunotherapy trials consistently
show a delay in the separation of OS curves between treatment and
control arms, which could reﬂect the time needed for an immune
response to translate into a survival effect. In study MDX010-20, a
separation in OS curves between ipilimumab arms and the control
arm was not observed until 3 months after treatment [14] (Fig. 2).
The challenge associated with delayed OS curve separation is that
it increases the statistical power necessary to differentiate the treat-
ment and control arms. A recent analysis of immunotherapy trials
estimated that more than 2700 patients would be necessary to
achieve statistical power to detect a signiﬁcant difference between
OS curves that showed a delayed separation of up to 6 months
[63]. An alternative approach might be to design a trial in which
landmark analysis is used to assess survival. However, there are also
challenges associated with this approach, including the long time
required for all patients to reach the landmark.
Median OS and landmark analysis may not fully capture the
survival beneﬁt of ipilimumab. For example, in the previously
mentioned meta-analysis of ipilimumab survival data, median OS
(11.4 months [95% CI, 10.7–12.1]) and landmark survival at 3 years
(22%) by themselves do not fully portray the complete survival
beneﬁt that may be achieved with ipilimumab [18]. In the pooled
analysis, a plateau in the Kaplan–Meier curve began at approxi-
mately 3 years and extended through follow-up of as long as
10 years, suggesting that in ipilimumab clinical trials, approxi-
mately 20% of patients with advanced melanoma experienced
long-term survival beneﬁt.
In order to fully characterize the survival pattern associatedwith
immunotherapy treatment, additional statistical models to assess
Fig. 1. Combined immune-checkpoint inhibition for melanoma treatment. Immune cells and tumor cells express multiple immune-checkpoints, which are being targeted for
melanoma treatment. Ipilimumab, an anti-CTLA-4 antibody, increases the number of activated T-cells migrating to attack the tumor by restoring an essential co-stimulatory
signal required to activate a T-cell immune response. Nivolumab, an anti-PD-1 antibody, prevents T-cell inactivation and promotes T-cell reactivation by disrupting the
interaction between PD-1 and its ligand, PD-L1. Since ipilimumab and nivolumab target two distinct immune-checkpoint pathways that mediate different aspects of the
adaptive immune response, combined immune-checkpoint inhibition with these agents may produce a more comprehensive immune response than that which can be
produced with either agent alone. CTLA-4, cytotoxic T-lymphocyte-associated antigen 4; MHC, major histocompatibility complex; PD-1, programmed death-1; PD-L1,
programmed death ligand-1. Figure reprinted by permission from Macmillan Publishers Ltd: Nature Reviews Clinical Oncology, Drake CG, Lipson EJ, Brahmer JR. Breathing
new life into immunotherapy: review of melanoma, lung and kidney cancer. Nat Rev Clin Oncol 2014;11(1):24–37, copyright 2014. [36].
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prospectively incorporate landmark analysis, conditional probabil-
ity of survival at speciﬁc time points, probability of relapse, and
other nontraditional metrics to describe HRs as a function of
time to provide a more accurate assessment of immunotherapyFig. 2. Kaplan–Meier analysis of overall survival in study MDX010-20. A separation in
observed after 3 months of treatment. A plateau in the Kaplan–Meier curves for the
glycoprotein 100 melanoma peptide vaccine; HR, hazard ratio; OS, overall survival. Figu
Sons, Inc., from New England Journal of Medicine, Hodi FS, O’Day SJ, McDermott DF, Web
with Metastatic Melanoma, vol. 363, p. 716, copyright  2010 Massachusetts Medical S
ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melano
copyright  2013 [62]; permission conveyed through Copyright Clearance Center, Inc..treatment. Also helpful will be future clinical trials testing neoadju-
vant therapy with these agents, as used successfully in breast
cancer, to provide a better assessment of the pathological response
histologically, as well as allowing examination of biomarker
expression on residual tumor.the Kaplan–Meier curves between the ipilimumab arms and the control arm is
ipilimumab arms is observed after approximately 2 years of treatment. gp100,
re adapted with permission from Massachusetts Medical Society and John Wiley &
er RW, Sosman JA, Haanen JB, et al. Improved Survival with Ipilimumab in Patients
ociety [14] and from Annals of the New York Academy of Sciences, Development of
ma, Wolchok JD, Hodi FS, Weber JS, Allison JP, Urba WJ, Robert C, et al, vol. 1291, p. 6,
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As the treatment landscape for melanoma becomes increasingly
complicated, clinicians who treat advanced melanoma will require
more information regarding the use of immunotherapies and other
agents in order to provide the greatest beneﬁt/risk for their
patients. There are a number of emerging questions that need to
be addressed to help clinicians make treatment decisions regarding
immunotherapy.
Since the majority of long-term immunotherapy data in mela-
noma is with ipilimumab, it is possible, but not conﬁrmed, that
the experience with this agent can be applied to immunotherapy
for melanoma in general. While data from ipilimumab clinical trials
suggest that CTLA-4 blockade produces durable response patterns
in a subset of melanoma patients, it is not yet known whether
PD-1 blockade or combined CTLA-4/PD-1 blockade will have a sim-
ilar effect. In a phase III study, ipilimumab 3 mg/kg was active
regardless of burden of disease and number/sites of metastases,
including metastases to the brain [14]. However, central nervous
system involvement in melanoma is frequently responsible for
treatment failure and death [64]; therefore, the effectiveness of ipi-
limumab in melanoma patients with brain metastases continues to
be explored [43,49,65] (EUDRACT Number 2012-004301-27). Data
derived from ipilimumab clinical trials also suggest that clinical
responses may be delayed, raising the concern that the underlying
diseasemay progress before an elicited immune response can coun-
ter the disease process. Given this possibility, it may be important
for the treating physician to consider disease tempo when making
treatment decisions related to immunotherapy.
Because the subpopulation that experiences long-term beneﬁt
with ipilimumab remains to be effectively characterized, another
challenge is deciding when to move a patient who is receiving ipi-
limumab on to the next therapy. Prescribers who are experienced
with ipilimumab cite anecdotal evidence that not only histologi-
cal/radiological data, but also patient performance status, are valu-
able in determining whether a patient is doing well on ipilimumab
or whether another therapy is needed. A related challenge is deter-
mining whether immunotherapy or targeted agents should be used
in the ﬁrst-line setting [66]. Prospective sequence trials will be
needed to determine which treatment regimens are optimal for
providing long-term survival beneﬁt.
Whether relapsing patients should receive retreatment, a differ-
ent agent, or a combination of agents also remains to be deter-
mined. Patients who progress after ipilimumab therapy may
subsequently beneﬁt from retreatment [14,56]. The National Com-
prehensive Cancer Network endorses consideration of retreatment
with ipilimumab for patients who experience progression follow-
ing initial clinical response or SD > 3 months, provided there are
no contraindications such as history of severe autoimmune disease
or toxicity [67]. The contribution of retreatment to overall survival
remains to be determined.Summary
Advances in immunotherapy and targeted therapy have revolu-
tionized the treatment landscape for advanced melanoma, raising
survival expectations beyond those historically anticipated with
this disease. The beneﬁts associated with these new therapies are
accompanied by limitations, which may be overcome by using
novel combination strategies. In order to maximize the impact of
immunotherapy in melanoma treatment, several important issues
need to be addressed. Biomarkers are needed to identify patients
who are most likely to respond to immunotherapy. In addition,
improved clinical trial endpoints are needed to fully capture the
clinical beneﬁts associated with immunotherapy. Finally, bestpractices need to be established to optimize the outcomes that
can be achieved with immunotherapy and targeted therapy.Conﬂict of interest
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